JW (Cayman) Therapeutics Co. Ltd
JWCTF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.18B
Close$
Share Statistics
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.33 |
| Beta | 1.9 |
| Outstanding Shares | 416,597,000 |
Return
| Return on Equity | -210.28% |
|---|---|
| Return on Assets | -114.18% |
| Return on Invested Capital | -116.58% |
Valuation & Multiples
| P/E Ratio | -3.01 |
|---|---|
| PEG | 3.71 |
| Price to Sales | 0.2 |
| Price to Book Ratio | 0.2 |
| Enterprise Value to Revenue | 2.28 |
| Enterprise Value to EBIT | -1.75 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.6 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About JW (Cayman) Therapeutics Co. Ltd
303 employees
CEO: Tian Feng JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumo...